Reply to E. C. Smyth et al

Affiliations

¹ Academic Medical Center of Amsterdam, Amsterdam, the Netherlands m.c.hulshof@amc.uva.nl.
² Academic Medical Center of Amsterdam, Amsterdam, the Netherlands.
³ Erasmus Medical Center, Rotterdam, the Netherlands.

Comment

Maarten C C M Hulshof et al. J Clin Oncol. 2014.

. 2014 Sep 20;32(27):3081-2.

doi: 10.1200/JCO.2014.56.3866. Epub 2014 Jul 28.

¹ Academic Medical Center of Amsterdam, Amsterdam, the Netherlands m.c.hulshof@amc.uva.nl.
² Academic Medical Center of Amsterdam, Amsterdam, the Netherlands.
³ Erasmus Medical Center, Rotterdam, the Netherlands.

No abstract available

Comment on

Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.
Oppedijk V, van der Gaast A, van Lanschot JJ, van Hagen P, van Os R, van Rij CM, van der Sangen MJ, Beukema JC, Rütten H, Spruit PH, Reinders JG, Richel DJ, van Berge Henegouwen MI, Hulshof MC. Oppedijk V, et al. J Clin Oncol. 2014 Feb 10;32(5):385-91. doi: 10.1200/JCO.2013.51.2186. Epub 2014 Jan 13. J Clin Oncol. 2014. PMID: 24419108 Clinical Trial.
Optimal management of esophageal adenocarcinoma: should we be CROSS?
Smyth EC, Waddell TS, Cunningham D. Smyth EC, et al. J Clin Oncol. 2014 Sep 20;32(27):3080-1. doi: 10.1200/JCO.2014.55.5243. Epub 2014 Jul 28. J Clin Oncol. 2014. PMID: 25071100 No abstract available.